HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

EG 6

structure given in first source

Also Known As:

1-(2-(2-(octadecyloxy)ethoxy)ethoxy)butylpyridinium; EG-6

Networked: 14 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Pyridinium Compounds: 5
      - EG 6: 14

Experts

1.	Henderson, Christopher E: 1 article (01/2022)
2.	Hornby, T George: 1 article (01/2022)
3.	Lotter, Jennifer K: 1 article (01/2022)
4.	Lucas, Emily: 1 article (01/2022)
5.	Plawecki, Abbey: 1 article (01/2022)
6.	Scofield, Molly E: 1 article (01/2022)
7.	Geoghegan, Cara E: 1 article (08/2021)
8.	Hrynewycz, Nadia M: 1 article (08/2021)
9.	Jadczak, Caroline N: 1 article (08/2021)
10.	Jenkins, Nathaniel W: 1 article (08/2021)

Related Diseases

1.	Hemorrhage 12/01/2003 - "The aggregate clinical research evidence supports the following general conclusions about the relationship between the timing of the first anticoagulant dose and the efficacy and safety of prophylaxis: (1) preoperative initiation is not required for good efficacy and, when begun within 2 h of surgery, increases major bleeding; (2) initiation at 6 h postoperatively is effective and not associated with increased major bleeding; (3) initiation < 6 h postoperatively increases major bleeding, without improved efficacy; thus, 6 h appears to be the threshold for early postoperative administration; and (4) initiation 12 to 24 h postoperatively may be less effective than initiation at 6 h, but further randomized trials comparing the same anticoagulant initiated at different times postoperatively (eg, 6 h vs 12 h) are required to establish definitively the optimal timing of the first anticoagulant dose."
2.	Sarcoidosis (Schaumann Disease) 01/01/2023 - "This study will address two clinical practice needs: (1) development of a risk calculator that provides an estimate of the likelihood of pulmonary progression in sarcoidosis patients during the follow-up period and (2) determine the optimal interval for serial clinical monitoring (eg, 6, 12, 18 months) using these risk prediction tools. "
3.	Neoplasms (Cancer) 07/01/1997 - "For the mammographic diagnoses "probably benign," "indeterminate," and "suggestive of malignancy or malignant," the probability of malignancy in aspirates of adequate cellularity (eg, > 6 epithelial groups) was 9%, 40%, and 93%, respectively. " 08/30/2018 - "Baseline and 6-month assessments will include anthropometric measures, functional tests (eg, 6-minute walk test and upper and lower limb strength), blood draws, patient-reported surveys (eg, quality of life and fatigue), and clinical markers of tumor progression (eg, Response Evaluation Criteria In Solid Tumors criteria). "
4.	Chronic Obstructive Pulmonary Disease (COPD) 01/01/2017 - "Field exercise tests (eg, 6-minute walk test [6MWT]) are important measures of functional exercise capacity in people with COPD. "
5.	Stroke (Strokes) 01/01/2022 - "Many physical therapist interventions provided to individuals with chronic stroke can lead to gains in gait speed or endurance (eg, 6-Minute Walk Test [6MWT]), although changes in objective measures of participation are not often observed. "

Related Drugs and Biologics

1.	Anticoagulants
2.	Biomarkers (Surrogate Marker)
3.	Glucuronides
4.	Pyrimidine Dimers
5.	Proteins (Proteins, Gene)
6.	Papaverine
7.	Opium
8.	Noscapine (Narcotine)
9.	Morphine (MS Contin)
10.	Ethylene Glycols